Core Insights - The active management equity funds are experiencing a strong recovery in returns, with 95% achieving positive returns and an average return exceeding 15% as of August 7, 2025 [1][2] - The pharmaceutical sector has emerged as the biggest winner, with four funds doubling their returns, all focused on this industry [3] Fund Performance - As of August 7, 2025, the average return for over 4,500 active equity funds is 15.03%, while more than 93% of over 2,500 stock index funds have positive returns averaging 11.8% [2] - Active equity funds have outperformed major indices like CSI 300 (4.6%) and CSI 500 (10.6%) after three years of underperformance [2] Fund Manager Dynamics - There are 90 active equity fund managers managing over 10 billion yuan, with Zhang Kun from E Fund leading at over 50 billion yuan [5][6] - Among these managers, 86 have achieved positive returns, with the average return for those managing over 30 billion yuan being 9.8%, which is lower than the average of the top 90 managers [6] Sector Focus - The four funds that doubled their returns are primarily invested in the pharmaceutical sector, including Changcheng Pharmaceutical Industry Selection and Huashan Pharmaceutical Biotechnology [3] - The top-performing managers, Zhang Wei and Zhang Lu, have focused on themes like innovative drugs and robotics, contributing to their high returns of 65.8% and 53.4% respectively [8] Underperforming Funds - Despite the overall positive trend, 228 active equity funds reported negative returns, with the worst performer, Qianhai Kaiyuan AI A, showing a return of -18.5% [3] - Wang Mingxu from GF Fund has seen 7 out of 8 funds underperform, with a bottom return of -7.4% [8][9] Investor Sentiment - Although the A-share market has been rising, investor confidence in active equity funds remains low, with a significant reduction in total shares of active equity funds by approximately 198.24 billion shares in the first half of 2025 [3]

Group 1 - The core viewpoint of the articles indicates a strong recovery in the performance of actively managed equity funds in 2025, with 95% of these funds achieving positive returns and an average return exceeding 15% as of August 7 [2][3] - The pharmaceutical sector has emerged as the biggest winner, with four actively managed equity funds achieving returns that have doubled this year, all focusing on the pharmaceutical industry [4][5] - As of mid-2025, there are 90 fund managers managing over 10 billion yuan, with Zhang Kun from E Fund leading with over 50 billion yuan under management [8][9] Group 2 - The average return of actively managed equity funds has outperformed major stock indices, such as the CSI 300 and the CSI 500, which recorded returns of 4.6% and 10.6% respectively [3] - The average return of the entire market of over 4,500 actively managed equity funds is 15.03%, compared to 11.8% for over 2,500 stock index funds [3] - Despite the overall positive performance, there are still 228 actively managed equity funds with negative returns, with the worst performer, Qianhai Kaiyuan AI A, showing a return of -18.5% [4][6] Group 3 - The top-performing funds in the pharmaceutical sector include Changcheng Pharmaceutical Industry Selection, Bank of China Hong Kong Stock Connect Pharmaceutical, Yongying Pharmaceutical Innovation Selection, and Huashan Pharmaceutical Biotechnology, all achieving significant returns [4][5] - The performance of fund managers varies significantly, with some, like Zhang Wei and Zhang Lu, achieving returns of 65.8% and 53.4% respectively, while others, such as Wang Mingxu, have negative returns [12][13] - The total scale of actively managed equity funds reached 3.39 trillion yuan by mid-2025, although the total number of shares decreased by 198.24 billion compared to the end of the previous year [6][7]

Core Viewpoint - The resignation of Zhang Kun, a prominent figure in the mutual fund industry, reflects significant adjustments in the management structure of E Fund this year, indicating a strategic shift towards focusing on investment management rather than executive roles [2][4]. Management Changes - E Fund announced the resignation of Zhang Kun as Vice President due to "work adjustments," effective May 15, 2025, while he will continue to focus on investment management [2][4]. - Zhang Kun has been with E Fund since 2008 and has played a crucial role in the active equity research team, managing funds totaling 60.822 billion yuan as of the first quarter [4]. - This resignation is part of a broader trend within E Fund, as other executives like Chen Hao and Xiao Nan have also stepped down from management roles to concentrate on fund management [8]. Industry Trends - There is a growing trend in the mutual fund industry where executives with investment backgrounds are choosing to "lighten their load" by stepping down from management positions to focus on investment [11]. - The increasing competition and market volatility in the mutual fund sector have led to heightened performance pressure on fund managers, making it more beneficial for them to concentrate on investment rather than administrative duties [11][12]. - Regulatory reforms are pushing fund companies to establish performance-based assessment systems, which may further incentivize fund managers to prioritize investment performance over management responsibilities [13].